First-in-class clascoterone opens a new door for acne care
Clascoterone 1% cream (Winlevi, Cassiopea) is a first-in-class topical androgen receptor. Its efficacy and safety for treating moderate-to-severe acne and reducing noninflammatory and inflammatory lesions was demonstrated in 2 pivotal trials including 1440 patients ages 9 years and older. Data from an open-label extension study provided evidence of safety during longer-term use. Studies of clascoterone […]